Zeltia Group

Zeltia S.A.: Report at 30 June 2005

    Madrid (ots/PRNewswire) - PharmaMar:

    - Orphan Drug designation granted by the FDA to Yondelis for the treatment of ovarian cancer in April.

    - Patient recruitment ongoing for the Phase III trial of Yondelis in ovarian cancer.

    - Promising results of Phase II trial of Yondelis in prostate cancer released at ASCO.

    - PharmaMar received 1 million dollars for complying with a milestone under the licensing and co-development contract with Johnson & Johnson.

    - Patient enrolment goal reached in the Phase II study of Yondelis in STS

    Other:

    - Zeltia increased capital, raising 65 million euro.

    - Group revenues amounted to 39 million euro.

    - The net cash position (cash + cash equivalents - short-term bank debt) amounted to 115 million euro.

    For further information please refer to www.zeltia.com

      Isabel Lozano
      CEO
      PharmaMar, S.A..U.
      C/ Reyes, 1. Colmenar Viejo
      Madrid
      Telephone: +34-91-846-60-00
      Catherine Moukheibir
      Head of Capital Market
      Strategy
      Zeltia, S.A.
      José Abascal, 2. Madrid
      Telephone: +34-91-444-45-00
      Ma Luisa de Francia
      CFO
      Zeltia, S.A.
      José Abascal, 2. Madrid
      Telephone: +34-91-444-45-00

ots Originaltext: Zeltia Group
Im Internet recherchierbar: http://www.presseportal.ch

Contact:
Isabel Lozano, CEO, PharmaMar, S.A..U., C/ Reyes, 1. Colmenar Viejo,
Madrid, Telephone: +34-91-846-60-00; Catherine Moukheibir, Head of
Capital Market, Strategy, Zeltia, S.A., José Abascal, 2. Madrid,
Telephone: +34-91-444-45-00; Ma Luisa de Francia, CFO, Zeltia, S.A.,
José Abascal, 2. Madrid, Telephone: +34-91-444-45-00



Das könnte Sie auch interessieren: